692 related articles for article (PubMed ID: 10953159)
1. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
2. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.
Harada S; Keller ET; Fujimoto N; Koshida K; Namiki M; Matsumoto T; Mizokami A
Prostate; 2001 Mar; 46(4):319-26. PubMed ID: 11241555
[TBL] [Abstract][Full Text] [Related]
3. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
5. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.
Sato N; Sadar MD; Bruchovsky N; Saatcioglu F; Rennie PS; Sato S; Lange PH; Gleave ME
J Biol Chem; 1997 Jul; 272(28):17485-94. PubMed ID: 9211894
[TBL] [Abstract][Full Text] [Related]
6. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
7. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP.
Mizokami A; Saiga H; Matsui T; Mita T; Sugita A
Endocrinol Jpn; 1992 Jun; 39(3):235-43. PubMed ID: 1425449
[TBL] [Abstract][Full Text] [Related]
8. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
[TBL] [Abstract][Full Text] [Related]
9. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract][Full Text] [Related]
10. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP
Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991
[TBL] [Abstract][Full Text] [Related]
11. JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA).
Ikezoe T; Yang Y; Taguchi H; Koeffler HP
Br J Cancer; 2004 May; 90(10):2017-24. PubMed ID: 15138488
[TBL] [Abstract][Full Text] [Related]
12. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
13. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
Yeap BB; Krueger RG; Leedman PJ
Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
Diao X; Chen X; Pi Y; Zhang Y; Wang F; Liu P; Gao Y; Wang X; Yang S; Lu S
Oncol Rep; 2018 Aug; 40(2):1174-1184. PubMed ID: 29917167
[TBL] [Abstract][Full Text] [Related]
15. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP.
Gong Y; Blok LJ; Perry JE; Lindzey JK; Tindall DJ
Endocrinology; 1995 May; 136(5):2172-8. PubMed ID: 7720667
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
18. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Rivest P; Renaud M; Sanderson JT
Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
20. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
